Amylyx Pharmaceuticals Reports Positive Safety Data for ALS Drug AMX0114 in Early Human Trials
Amylyx Pharmaceuticals has announced promising safety and tolerability data from its Phase 1 LUMINA trial of AMX0114, an investigational treatment for amyotrophic lateral sclerosis (ALS). The trial, which is the first human study of AMX0114, showed that the drug was generally well-tolerated with no treatment-related serious adverse events. The company plans to begin enrolling the second cohort of participants in Canada and the U.S. early next year. AMX0114 targets calpain-2, a protease involved in axonal degeneration, a key factor in ALS progression. 
